Navigation Links
NLST data highlight probability of lung cancer overdiagnosis with low-dose CT screening
Date:12/9/2013

Philadelphia, PAData from the National Lung Cancer Screening Trial (NLST)conducted by the American College of Radiology Imaging Network and National Cancer Institute Lung Screening Studyprovided researchers the opportunity to investigate the probability that a cancer detected with screening low-dose computed tomography (LDCT) would not have progressed to become life threatening. The results of this investigation published online today in JAMA Internal Medicine suggest that up to 18 percent of the cancers detected by LDCT may not have progressed enough to affect patient health if left undetected.

"This is another piece of important information that helps us to better understand the benefits and risks of lung cancer screening," says the study's lead author, Edward F. Patz, Jr., M.D., a professor of radiology, and pharmacology and cancer biology at Duke University School of Medicine.

"The NLST provided encouraging data demonstrating that lung cancer screening with CT reduces death from the disease. However, there are inherent risks with any mass screening program, and this paper investigates the probability of overdiagnosismeaning, if some patients never would have been screened for lung cancer, they would never have known they had the disease because it would never have caused symptom."

The specific negative consequences of overdiagnosis described by the authors include unnecessary invasive diagnostic procedures, treatment, morbidity (and mortality in rare cases), follow-up, cost, patient anxiety, and labeling of patients with a disease that otherwise would never have been detected.

Using NLST data, the authors determined an "upper bound to true overdiagnosis rate" because the post-screening follow-up period in NLST may not have been long enough to totally differentiate overdiagnosis from the effects of lead timethe length of time a diagnosis was moved up due to early detection by screening. The probability that any lung cancer (all types and stages) detected by screening with LDCT is an overdiagnosis was reported as 18.5 percent. The probability that an LDCT-detected non-small cell lung cancerby far the most frequently diagnosed lung cancer typerepresents an overdiagnosis was found to be 22 percent. The overdiagnosis rate for bronchioloalveolar lung cancer was 78.9 percent.

Patz explains that the problem clinicians face is not knowing which patients are among the approximate 18 percent who have indolent disease. "Patients with these nonaggressive cancers are treated the same as any other patient with lung cancer, because it is generally not possible to distinguish indolent lesions from more aggressive tumors," says Patz. The authors emphasize the need for better biomarkers and imaging techniques to determine which lung cancers are more or less aggressive so as to optimize patient care and enhance the value of screening programs.

"Overdiagnosis is something we don't commonly think exists in lung cancer as compared with, for example, prostate cancer," says Patz. "Most often, when patients are diagnosed with lung cancer, it's viewed as a fatal disease. However, these data confirm that's not necessarily the case with screening programs, which is important information for clinicians to discuss with their patients."

"The relatively modest rate of overdiagnosis with low-dose CT compared with the overdiagnosis rate projected for other cancer screenings programs, further supports the implementation of lung cancer screening programs. Of course, it's important that we work to further drive down overdiagnosis rates across all screening programs," says Mitchell D. Schnall, M.D., Ph.D., Co-Chair of the ECOG-ACRIN Cancer Research Group and the Radiology Department Chair at the University of Pennsylvania's Perelman School of Medicine.


'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related biology technology :

1. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
2. How to Enhance Scientific Intuition in Pharmaceutical R&D: the CBCD Highlights a Revolutionary New Technology
3. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
4. Bend Research to Highlight Latest Drug Formulation Technologies
5. Pittcon 2014 Announces Highlights of Annual Waters Symposium
6. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
7. SCAI Paper Highlights Best Practices For Diagnosing And Treating Blocked Arteries Via The Wrist
8. Apache's New Video Highlights Benefits of Employee Ownership
9. SACHEM Booth #1441 At SEMICON Europa Oct 8-10th, Highlighting Envure System™
10. The Zacks Analyst Blog Highlights: SPDR Health Care Select Sector Fund, SPDR S&P 500, SPDRS&P Biotech ETF, PowerShares S&P SmallCap Health Care Portfolio and PowerShares Dynamic Biotechnology & Genome Portfolio
11. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):